Cybin Inc. (CYBN)
NYSEAMERICAN: CYBN · Real-Time Price · USD
9.61
+0.29 (3.11%)
At close: Dec 20, 2024, 4:00 PM
9.66
+0.05 (0.52%)
After-hours: Dec 20, 2024, 7:58 PM EST
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
192.21M USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | - | - | - |
Mar 31, 2023 | - | - | - |
Mar 31, 2022 | - | - | - |
Mar 31, 2021 | 864.00K | - | - |
Mar 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Organigram Holdings | 118.32M |
ADC Therapeutics | 70.72M |
Mersana Therapeutics | 34.84M |
Inventiva | 20.65M |
Fate Therapeutics | 13.45M |
Perspective Therapeutics | 1.56M |
CYBN News
- 11 days ago - Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results - Business Wire
- 17 days ago - Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024 - Business Wire
- 4 weeks ago - Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder - Business Wire
- 5 weeks ago - Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024 - Business Wire
- 5 weeks ago - Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results - Business Wire
- 7 weeks ago - Cybin to Participate at the 2024 Milken Institute Future of Health Summit - Business Wire
- 2 months ago - Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Business Wire
- 2 months ago - Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha